BioCryst Appoints Vincent Milano to Board of Directors
July 28 2021 - 07:00AM
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that
the company has appointed hereditary angioedema (HAE) and rare
disease industry leader, Vincent Milano, to its board of directors.
Mr. Milano currently serves as chief executive
officer of Idera Pharmaceuticals, Inc., and previously served as
chairman, president and chief executive officer of ViroPharma,
which successfully developed and launched Cinryze for the treatment
of HAE in the United States and Europe, prior to its acquisition by
Shire in 2014. Prior to joining ViroPharma in 1996, he served as a
senior manager at KPMG LLP, an independent registered public
accounting firm.
“I have seen first-hand how valuable innovation
is for HAE and other rare disease patients and I am excited to join
alongside Jon and the board as BioCryst continues to leverage its
industry-leading combination of scientific and commercial rare
disease expertise to deliver its prolific pipeline of novel oral
medicines for rare diseases to patients,” Milano said.
“As we got to know Vin through our discussions
with Idera several years ago, we were incredibly impressed with his
deep and successful rare disease and HAE experience and we are
delighted to add his expertise to the BioCryst board as the company
brings ORLADEYO® (berotralstat) to HAE patients around the world
and advances its pipeline programs, like BCX9930,” said Robert
Ingram, chairman of BioCryst.
Mr. Milano currently serves on the boards of
directors of Idera Pharmaceuticals, Aclaris Therapeutics and
VenatoRx Pharmaceuticals, and is the chairman of the board for Life
Science Cares Philadelphia. He received his Bachelor of Science
degree in accounting from Rider College.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule
medicines that treat rare diseases in which significant unmet
medical needs exist and an enzyme plays a key role in the
biological pathway of the disease. Oral, once-daily ORLADEYO®
(berotralstat) is approved in the United States, the European
Union, Japan and the United Kingdom for the prevention of HAE
attacks in adults and pediatric patients 12 years and older.
BioCryst has several ongoing development programs including
BCX9930, an oral Factor D inhibitor for the treatment of
complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the
treatment of fibrodysplasia ossificans progressiva, and
galidesivir, a potential treatment for Marburg virus disease and
Yellow Fever. RAPIVAB® (peramivir injection), a viral
neuraminidase inhibitor for the treatment of influenza, has
received regulatory approval in the U.S., Canada, Australia, Japan,
Taiwan and Korea. Post-marketing commitments for RAPIVAB are
ongoing. For more information, please visit the company’s website
at www.biocryst.com.
Forward-Looking Statements
This press release contains forward-looking
statements, including statements regarding future results,
performance or achievements. These statements involve known and
unknown risks, uncertainties and other factors which may cause
BioCryst’s actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. These statements reflect our current views with respect
to future events and are based on assumptions and are subject to
risks and uncertainties. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Some of
the factors that could affect the forward-looking statements
contained herein include: the ongoing COVID-19 pandemic, which
could create challenges in all aspects of BioCryst’s business,
including without limitation delays, stoppages, difficulties and
increased expenses with respect to BioCryst’s and its partners’
development, regulatory processes and supply chains, negatively
impact BioCryst’s ability to access the capital or credit markets
to finance its operations, or have the effect of heightening many
of the risks described below or in the documents BioCryst files
periodically with the Securities and Exchange Commission;
BioCryst’s ability to successfully implement its commercialization
plans for, and to commercialize ORLADEYO, which could take longer
or be more expensive than planned; the commercial viability of
ORLADEYO, including its ability to achieve market acceptance;
ongoing and future preclinical and clinical development of BCX9930,
BCX9250 and galidesivir may not have positive results; BioCryst may
not be able to enroll the required number of subjects in planned
clinical trials of product candidates; BioCryst may not advance
human clinical trials with product candidates as expected; the FDA,
EMA, PMDA or other applicable regulatory agency may require
additional studies beyond the studies planned for products and
product candidates, may not provide regulatory clearances which may
result in delay of planned clinical trials, may impose certain
restrictions, warnings, or other requirements on products and
product candidates, may impose a clinical hold with respect to
product candidates, or may withhold, delay or withdraw market
approval for products and product candidates; product candidates,
if approved, may not achieve market acceptance; BioCryst’s ability
to successfully manage its growth and compete effectively; risks
related to the international expansion of BioCryst’s business; and
actual financial results may not be consistent with expectations,
including that operating expenses and cash usage may not be within
management's expected ranges. Please refer to the documents
BioCryst files periodically with the Securities and Exchange
Commission, specifically BioCryst’s most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on
Form 8-K, all of which identify important factors that could cause
the actual results to differ materially from those contained in
BioCryst’s projections and forward-looking statements.
BCRXW
Investors:John Bluth+1 919 859
7910jbluth@biocryst.com
Media:Catherine Collier
Kyroulis+1 917 886 5586ckyroulis@biocryst.com
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioCryst Pharmaceuticals (NASDAQ:BCRX)
Historical Stock Chart
From Mar 2023 to Mar 2024